9fin’s Post

#JohnsonandJohnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. Still, Wall Street expects the New Brunswick, New Jersey-based pharmaceutical giant to post a dip in earnings when it reports back for the fourth quarter next Tuesday. J&J raised guidance raised its 2023 guidance to include adjusted operational sales growth of between 7.2% to 7.7% with a mid-point of 7.5%. Reported sales are seen between $84.4–$84.8 billion and adjusted earnings per share (EPS) is forecast between $10.02–$10.08. For the December quarter, the consensus estimate of analysts polled by Zacks Investment Research is for EPS of $2.27, down from $2.35 in 4Q 2022. More at #Proactive #ProactiveInvestors #NYSE #JNJ http://ow.ly/SRIh10596B1

Read our latest report for Otsuka Pharmaceutical Companies (U.S.)

Europe’s most valuable company, Novo Nordisk, reported Q2 earnings. The pharmaceutical company raised its outlook for revenue but cut forecast for operating profit. (DKK) Net profit 20.05B (Est. 20.09B) +3% YoY Revenue: 68.06B (Est. 68.47B) +25% YoY "We are pleased with the sales growth in the first half of 2024, which has enabled us to raise the outlook for the full year.” -Lars Fruergaard Jørgensen, CEO So far, the stock is down 2.43% in the Nasdaq Copenhagen. #novonordisk #earnings #pharmaceutical #stockmarket #company #companyearnings #finance #stocks

In the News: Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account for 41% of market growth 🌟 Discover the latest in the world of FDI and Business! Check out this insightful piece. 💡🌍 /PRNewswire/ -- The pharmaceutical contract manufacturing market is expected to grow by USD 58 billion from 2022 to 2027. In addition, the momentum of the... 🔗 [Learn more: https://lnkd.in/eBYAJAan] 🗨️ Join the Discussion! Your opinions are invaluable. #Comment below to share your views, ask questions, or start a conversation. We're excited to engage with each comment and hear what you think! Join as a Partner and Professional: FDI Alliance: www.fdialliance.com Valqus Accounting and Business: www.valqus.com #FDI #Invest #Trade #TradeandInvest #InvestmentPromotion #Markets #Business #Accounting

Outsourcing has become the norm in our industry, yet we still see issues on both sides of the table.   Preparing to outsource and selecting the right vendor is essential as pharmaceutical companies consolidate their third-party suppliers, seeking more strategic relationships to help reduce supply chain complexity and risk.  Hear from PCI Pharma Services Ed Groleau and fellow industry experts Jennifer Rose and Liz Sherman as they provide insights into how to decrease risk and increase success when partnering with third parties.   Find out more and register: https://lnkd.in/ej24UmMg #LetsTalkFuture #GCSG #ClinicalTrials  #ClinicaltrialManagement

It is critical that manufacturers are well equipped to deal with the potential obstacles and challenges they will face as they bring new products to the world’s two largest pharmaceutical markets, following implementation of the Inflation Reduction Act (IRA) in the United States and Joint Clinical Assessments (JCA) in the European Union. Join us for a webinar where we will compare and contrast these two seismic changes to the value and access landscape, and provide some best practices and experience-based key learnings to help manufacturers to prepare for the implications of these changes. Find out more and register for our webinar here: https://buff.ly/4d3Clby #LumanityPerspectives #InflationReductionAct #IRA #EUHTARegulation #EUHTA #JCA #HEOR

Competitive Intelligence and Pharmaceutical Industry According to an article by WNS Global Services, Competitive Intelligence (CI) is a crucial function for the pharma industry – to derive insights from data, anticipate competitor actions and re-calibrate strategies. CI is a nuanced domain that requires careful analysis. Specifically, for pharmaceutical companies, CI can deliver several benefits, including: • Enhanced Drug Development • Improved Due Diligence in Mergers and Acquisitions (M&As), and Licensing • Better Brand Positioning • Effective Portfolio Management • Insights for Market Penetration https://lnkd.in/ddFu28cQ #competitiveintelligence #pharmaceuticalindustry

📚 #ReadoftheWeek Sreedhar Patnala, General Manager at Systech International, explores how pharmaceutical companies are aligning their #sustainability goals with the complexities of the modern supply chain. Read more here: https://bit.ly/4chDQlB.

#FinancialModelFriday Thought of the Week: Use Excel functions to customize outputs of the Bloomberg Interactive Calculator (e.g., sort pharmaceutical company valuations from highest to lowest 2023 Ev/Ebitda). #financialmodeling #Excel